Abstract:BACKGROUND:Concurrent twice-daily radiotherapy with chemotherapy of EP regimen is one of the current standard treatments for limited-stage small cell lung cancer. However, the safely tolerated dose of standard chemotherapy for Chinese patients is not decided. This study was to evaluate the toxicity and the maximum tolerated dose (MTD) of etoposide and cisplatin concurrent with thoracic radiation therapy for patients with limited-stage small cell lung cancer.METHODS:Patients with histologically proven limited-stage small cell lung cancer (LS-SCLC) were eligible. The patients underwent thoracic radiotherapy (45 Gy, 1.5 Gy bid, 30 fractions for 3 weeks) delivered concurrently with etoposide (100 mg/m2 iv, days 1-3) and cisplatin dose escalating from the two levels ( 70 mg/m2 and 75 mg/m2 on d1). The primary endpoints were hematologic toxicities during treatment. The secondary endpoints were non-hematologic toxicities, overall survival (OS) and progression-free survival (PFS). According to Common Terminology Criteria for Adverse Events 4.0 (CTC-AE 4.0), maximum tolerant dosage (MTD) was defined as the highest safely tolerated dose at which no more than one patient out of six experiences dose-limiting toxicity (Grades 4 hematologic), with the next higher dose having at least two out of six patients experience dose-limiting toxicity.RESULTS:From January 2013 to August 2016, 20 patients were enrolled in this study. The median age was 49.5 (30-68). After the first 6 patients were enrolled in Arm 1 (70 mg/m2 on d1), one patient had Grade 4 neutropenia. Another 14 patients were enrolled in Arm 2 (75 mg/m2 on d1), one patient had Grade 4 neutropenia. The MTD was determined to be etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). 4 patients had ≥Grade 3 neutropenia and 1 patients had ≥Grade 3 acute esophagitis in Arm 1. 10 patients had ≥Grade 3 neutropenia and no patient had ≥Grade 3 acute esophagitis in Arm 2. All patients with a median follow-up time was 9.0 months, median OS and PFS were not achieved, 1-year OS and PFS were 91% and 61%, respectively.CONCLUSIONS:The MTD of RT with concurrent chemotherapy of EP regimen for patients with LS-SCLC was etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). .

Clinical and Pharmacokinetics Study of Oral Low-dose Etoposide in Non-smiallcell Lung Cancer

Efficacy and Safety of Oral Etoposide on Heavily Pretreated Metastatic Breast Cancer

Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation with Concurrent Twice-daily Radiotherapy for Patients with Limited-stage Small Cell Lung Cancer

The Benefits of Etoposide Capsules As Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: a Prospective Two-Stage, Two-Center Study

Low Dose Efficacy of Etoposide on Conventional Treatment-Refractory Adult-Onset Still Disease

Etoposide plus lobaplatin versus etoposide plus cisplatin for patients with extensive stage small cell lung cancer:A Meta -analysis

A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer

Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer.

Clinical Observation of Topotecan and Etoposide Plus Cisplatin in Treating Small Cell Lung Cancer

Adverse reactions and prognosis of Lobaplatin combined with Etoposide in the treatment of primary small cell lung cancer

Comparative Study of Iobaplatin and Cisplatin Combined with Etoposide for Advanced Small Cell Lung Cancer

The Efficacy and Relationship Between Peak Concentration and Toxicity Profile of Fixed-Dose-Rate Gemcitabine Plus Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer

Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial

1797P Efficacy and safety analysis of EP / EC regimen combined with first-line anlotinib hydrochloride in the treatment of extensive small cell lung cancer: Results from a phase II single-arm trial

Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation

Preparation of etoposide liposomes for enhancing antitumor efficacy on small cell lung cancer and reducing hematotoxicity of drugs

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis

A Randomized, Multicenter Phase III Study of Lobaplatin/etoposide Versus Cisplatin/etoposide As First-Line Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer and Circulating Tumor Cells (ctcs) As an Exploratory Biomarker.

Clinical study of oxaliplatin combined with gemcitabine for advanced non-small cell lung cancer(NSCLC)

Randomized Trial of High-dose Epirubicin for the Treatment of Non-small Cell Lung Cancer

Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-cell Lung Cancer